HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Marketing in Brief: Escada Beaute

This article was originally published in The Rose Sheet

Executive Summary

Escada Beaute: Que Viva, a "fruity, floral" seasonal fragrance, will be on counter March 1, according to Adipar, the company's New York City-based distribution subsidiary. Supplied by Creations Aromatiques, the scent opens with notes of passion fruit and pineapple, leading to a heart of rose, jasmine, violet, figs, grapes and plums. Sandalwood, cedar and vanilla tree flower accords comprise the drydown. Packaged in a "vivid blue" heart-shaped bottle with a gold cap, a 1 oz. Que Viva eau de toilette will retail for $35. A 1.7 oz. edt spray will cost $45 and a 3.4 oz. edt spray will sell for $65. A 5.1 oz. shower gel and 5.1 oz. body lotion will cost $25 and $30, respectively. Escada is also planning to launch a new men's fragrance and an extension to its Acte 2 scent this spring...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS003543

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel